Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;19(12):e0295462.
doi: 10.1371/journal.pone.0295462. eCollection 2024.

HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review

Argyro Karakosta  1   2 , Elisa Ruiz-Burga  1 , Shema Tariq  1   3 , Giota Touloumi  2 , Emily Jay Nicholls  1 , Nikos Pantazis  2 , Inma Jarrin  4   5 , Marc Van der Valk  6   7 , Caroline Sabin  1 , Cristina Mussini  8 , Laurence Meyer  9 , Alain Volny Anne  10 , Christina Carlander  11 , Sophie Grabar  12 , Linda Wittkop  13   14 , Bruno Spire  15 , Jonh Gill  16 , Kholoud Porter  1 , Fiona Burns  1 ; for CASCADE Collaboration
Affiliations

HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review

Argyro Karakosta et al. PLoS One. .

Abstract

Background: Individuals who have recently acquired HIV represent a unique population because the time frame since HIV acquisition is relatively short and identification of missed HIV prevention opportunities is, therefore, closer to real time and less subject to recall bias. Identifying prevention measures used and missed opportunities for using them, can help stop further HIV transmission.

Objectives: This systematic review aims to synthesise current global evidence on uptake of HIV prevention methods among people with recently acquired HIV from 2007, the year that the concept of ART as a prevention method was first introduced.

Methods and analysis: MEDLINE/PubMed, EMBASE, PsycINFO, Cochrane and Web of Science databases, will be searched for articles published January 2007-December 2023. Eligible studies will be those that reported on HIV prevention methods among people with recently acquired HIV. Quality assessment of the studies selected will be undertaken, and reporting of the systematic review will be informed by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: The systematic review is expected to provide comprehensive insights into the uptake, use and adherence to HIV prevention methods among individuals with recently acquired HIV. Analysis anticipates identifying gaps in prevention coverage, missed opportunities for intervention, and variations in access to and use of prevention strategies. Sociodemographic, personal, and behavioural factors influencing prevention uptake and adherence will also be synthesised.

Conclusions: The findings will be of key relevance to researchers, healthcare providers including third sector organisations/ community groups and policymakers, as they will offer insight into better understanding of missed or failed HIV prevention efforts and will help ensure future efforts meet the needs of those in need of them.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The funders did not participate in the study design and will not intervene in its process, analysis or publication of the findings. ST has received speaker honoraria and consultancy fees from Gilead Sciences. CC has received speaker/moderator honoraria and advisory board fees from Gilead Sciences, GSK/ViiV and MSD as well as an unrestricted Gilead Sciences Nordic Fellowship Research Grant. CS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for participation in Advisory Boards, speaker panels and for preparation of educational materials. MVdV has received consultancies fees for participation in advisory boards and research grants from Gilead, MSD and ViiV all paid to his institution. FB has received funding from Gilead Sciences Ltd for preparation and delivery of educational materials. IJ has received teaching fees from ViiV Healthcare and advisory fees from Gilead Sciences. GT has received research grants and advisory board fees from Gilead, all paid to her institution, and MJG has received honoraria for ad hoc participation in national Advisory boards of Gilead Merck and ViiV.

Similar articles

See all similar articles

References

    1. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al.. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816 - DOI - PMC - PubMed
    1. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al.. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet 2019;393(10189):2428–38. doi: 10.1016/S0140-6736(19)30418-0 - DOI - PMC - PubMed
    1. UNAIDS (2021). Global AIDS Strategy 2021–2026 –End Inequalities. End AIDS. URL: https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS... [accessed 2023-28-07]
    1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al.. On-Demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46. doi: 10.1056/NEJMoa1506273 - DOI - PubMed
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al.. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016;387(10013):53–60. doi: 10.1016/S0140-6736(15)00056-2 - DOI - PMC - PubMed

MeSH terms